Skip to main content

Rosetta Genomics Ltd. has received regulatory approval for their diagnostic test using MicroRNA technology to differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC).

At present, the test is approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program and is expected to become available nationwide at the end of 2008. The diagnostic test utilizes a tumor tissue sample for MicroRNA testing with a sensitivity and specificity of over 90% for identification of squamous cell NSCLC.

Scroll to Continue

Recommended Articles

Ovarian Cancer

Treatment & Management of Ovarian Cancer

Understand the role of surgery, chemotherapy, and precision cancer medicines in the treatment of Ovarian Cancer.

Image placeholder title

Precision Cancer Medicines for Ovarian Cancer

Genomic testing identifies targets that can be treated with precision cancer medicines. ASCO 2021 update

Image placeholder title

Liquid Biopsies Replacing Tissue-based Tests and Improving Treatment

NGS and biomarker testing with liquid biopsies improve treatment and should be performed in all newly diagnosed NSCLC patients.